(NDRM) - Earnings & Price History

NDRM: - 38.85, $1.02B, 0.00 (0.00%)

Sector: Healthcare - Industry: Biotechnology

NeuroDerm Ltd., a clinical-stage pharmaceutical company, engages in developing products for the treatment of central nervous system (CNS) disorders. The companys product candidates, which have completed Phase IIa clinical trial, include ND0612H for the treatment of patients with severe Parkinsons disease; and ND0612L for the treatment of patients with moderate stage of Parkinson's disease. It is also developing ND0801, which is in Phase IIa clinical trial for the treatment of cognition disorders associated with CNS diseases, such as ADD/ADHD, Alzheimers disease, and schizophrenia; and ND0701, an apomorphine-based product candidate for the treatment of moderate to severe Parkinsons disease. NeuroDerm Ltd. was founded in 2003 and is headquartered in Rehovot, Israel.Key Statistics

Past NDRM reports
Earning DateTimeTitleEPS-e EPS-a ClosePrev CloseOpen Day LowDay High Gap % CFO %Change % Volume
2016-11-10BMO-0.4217.5517.517.3517.0517.9-0.86%▲1.15%0.29%106.44K
2016-08-25BMO-0.3216.516.917.516.3617.53.55%-5.71%-2.37%27.82K
2016-08-05BMO-0.3218.6718.9219.0918.5119.150.90%-2.20%-1.32%22.79K
2016-08-04BMO-0.3218.9218.5218.3718.3719.03-0.81%2.99%2.16%25.22K
2016-05-26BMO-0.3518.1217.8717.8717.6518.351.40%1.40%69.83K
2016-03-31BMO-0.2914.1214.3613.9513.514.48-2.86%1.22%-1.67%168.83K
2015-11-11BMO-0.3417.5618.8621.516.2421.514.00%▲-18.33%-6.89%727.06K
2015-08-06-0.217.9818.418.2817.4418.28-0.65%-1.64%-2.28%216.36K
2015-05-27-0.2812.9112.9212.9412.8513.250.15%-0.23%-0.08%154.11K

Login | Register
Friday Nov 16, 2018   EST
Enter a Ticker:

Economic Calendar

AAII Sentiment Survey

BULL^ neut ^ BEAR

Chart

index chart
index color
SPY257.6450.500.19%41,867,194

Upgrades/Downgrades